181
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 2, 2022Completed
Refractory Multiple Myeloma: 1456 Clinical Trials, Page 19 of 146
Hide Studies Not Open or Pending
182
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Condition(s):Multiple MyelomaLast Updated:December 15, 2022Active, not recruiting
183
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Condition(s):Relapsed and/or Relapsed-refractory Multiple MyelomaLast Updated:October 23, 2020Terminated
184
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition(s):Relapsed/Refractory Multiple Myeloma; Plasma Cell LeukemiaLast Updated:March 8, 2023Not yet recruiting
185
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Condition(s):Relapse/Refractory Multiple MyelomaLast Updated:May 14, 2018Withdrawn
186
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:December 17, 2020Completed
187
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 23, 2023Recruiting
188
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:January 10, 2018Completed
189
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition(s):Relapsed/Refractory Multiple Myeloma; Plasma Cell LeukemiaLast Updated:May 24, 2022Recruiting
190
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 28, 2023Recruiting